AJANTPHARMPharmaceuticals
Ajanta Pharma Ltd — Profit & Loss Statement
₹2805.10
-2.50%
Ajanta Pharma Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.43 Cr | 7.57 Cr | -1.97 Cr | 4.66 Cr | — |
| Tax Rate For Calcs | 0.23 | 0.27 | 0.21 | 0.22 | — |
| Normalized EBITDA | 1.35K Cr | 1.23K Cr | 891.24 Cr | 1.02K Cr | — |
| Total Unusual Items | 1.92 Cr | 28.32 Cr | -9.35 Cr | 21.52 Cr | — |
| Total Unusual Items Excluding Goodwill | 1.92 Cr | 28.32 Cr | -9.35 Cr | 21.52 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 920.39 Cr | 816.17 Cr | 587.98 Cr | 712.68 Cr | — |
| Reconciled Depreciation | 144.11 Cr | 135.40 Cr | 130.80 Cr | 125.30 Cr | — |
| Reconciled Cost Of Revenue | 1.13K Cr | 1.12K Cr | 1.12K Cr | 886.72 Cr | — |
| EBITDA | 1.35K Cr | 1.26K Cr | 881.89 Cr | 1.04K Cr | — |
| EBIT | 1.21K Cr | 1.12K Cr | 751.09 Cr | 919.68 Cr | — |
| Net Interest Income | 26.43 Cr | 20.50 Cr | 2.62 Cr | 4.45 Cr | — |
| Interest Expense | 20.73 Cr | 7.21 Cr | 5.84 Cr | 10.20 Cr | — |
| Interest Income | 47.16 Cr | 27.71 Cr | 8.46 Cr | 14.65 Cr | — |
| Normalized Income | 918.90 Cr | 795.42 Cr | 595.36 Cr | 695.82 Cr | — |
| Net Income From Continuing And Discontinued Operation | 920.39 Cr | 816.17 Cr | 587.98 Cr | 712.68 Cr | — |
| Total Expenses | 3.46K Cr | 3.12K Cr | 3.03K Cr | 2.47K Cr | — |
| Rent Expense Supplemental | 9.33 Cr | 7.38 Cr | 7.59 Cr | 6.54 Cr | — |
| Diluted Average Shares | 12.52 Cr | 12.60 Cr | 12.81 Cr | 12.97 Cr | — |
| Basic Average Shares | 12.51 Cr | 12.59 Cr | 12.81 Cr | 12.97 Cr | — |
| Diluted EPS | 73.53 | 64.77 | 45.89 | 54.96 | — |
| Basic EPS | 73.56 | 64.82 | 45.89 | 54.97 | — |
| Diluted NI Availto Com Stockholders | 920.39 Cr | 816.17 Cr | 587.98 Cr | 712.68 Cr | — |
| Average Dilution Earnings | 0.00 | 0.00 | 0.00 | — | 0.00 |
| Net Income Common Stockholders | 920.39 Cr | 816.17 Cr | 587.98 Cr | 712.68 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 920.39 Cr | 816.17 Cr | 587.98 Cr | 712.68 Cr | — |
| Net Income Including Noncontrolling Interests | 920.39 Cr | 816.17 Cr | 587.98 Cr | 712.68 Cr | — |
| Net Income Continuous Operations | 920.39 Cr | 816.17 Cr | 587.98 Cr | 712.68 Cr | — |
| Tax Provision | 268.77 Cr | 297.76 Cr | 157.27 Cr | 196.80 Cr | — |
| Pretax Income | 1.19K Cr | 1.11K Cr | 745.25 Cr | 909.48 Cr | — |
| Other Non Operating Income Expenses | 4.14 Cr | 3.59 Cr | 6.15 Cr | 15.29 Cr | — |
| Special Income Charges | -0.60 Cr | 3.49 Cr | -5.35 Cr | -7.85 Cr | — |
| Other Special Charges | 0.60 Cr | -3.49 Cr | 5.35 Cr | 3.87 Cr | — |
| Net Non Operating Interest Income Expense | 26.43 Cr | 20.50 Cr | 2.62 Cr | 4.45 Cr | — |
| Interest Expense Non Operating | 20.73 Cr | 7.21 Cr | 5.84 Cr | 10.20 Cr | — |
| Interest Income Non Operating | 47.16 Cr | 27.71 Cr | 8.46 Cr | 14.65 Cr | — |
| Operating Income | 1.13K Cr | 1.05K Cr | 679.76 Cr | 811.88 Cr | — |
| Operating Expense | 2.33K Cr | 2.00K Cr | 1.91K Cr | 1.59K Cr | — |
| Other Operating Expenses | 689.72 Cr | 621.48 Cr | 672.90 Cr | 540.18 Cr | — |
| Depreciation And Amortization In Income Statement | 144.11 Cr | 135.40 Cr | 130.80 Cr | 125.29 Cr | — |
| Amortization | 8.22 Cr | 5.01 Cr | 4.10 Cr | 3.94 Cr | — |
| Depreciation Income Statement | 135.89 Cr | 130.39 Cr | 126.70 Cr | 121.35 Cr | — |
| Selling General And Administration | 459.12 Cr | 382.66 Cr | 342.68 Cr | 313.72 Cr | — |
| Selling And Marketing Expense | 302.00 Cr | 253.12 Cr | 226.71 Cr | 218.57 Cr | — |
| General And Administrative Expense | 157.12 Cr | 129.54 Cr | 115.97 Cr | 95.15 Cr | — |
| Rent And Landing Fees | 9.33 Cr | 7.38 Cr | 7.59 Cr | 6.54 Cr | — |
| Gross Profit | 3.46K Cr | 3.05K Cr | 2.59K Cr | 2.40K Cr | — |
| Cost Of Revenue | 1.13K Cr | 1.12K Cr | 1.12K Cr | 886.72 Cr | — |
| Total Revenue | 4.59K Cr | 4.16K Cr | 3.71K Cr | 3.28K Cr | — |
| Operating Revenue | 4.59K Cr | 4.16K Cr | 3.71K Cr | 3.28K Cr | — |
| Write Off | — | — | -0.84 Cr | 0.00 | — |
| Impairment Of Capital Assets | — | — | 0.02 Cr | 3.98 Cr | 7.56 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Ajanta Pharma Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.